ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year
"We are extremely pleased that ImmunoGen has once again been recognized
as one of
About
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for FRα-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including mirvetuximab soravtansine (IMGN853), including risks related
to clinical studies and regulatory processes, their timings and results.
A review of these risks can be found in ImmunoGen's Annual Report on
Form 10-K for the fiscal year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20151113005123/en/
info@immunogen.com
Source:
News Provided by Acquire Media